Neoadjuvant Chemotherapy and Radiation Improves Recurrence-free and Overall Survival in Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Jesse K KelleyHordur KolbeinssonSreenivasa ChandanaBenjamin EastburgAustin FrischJessica ParkerG Paul WrightM Mura AssifiMathew Chung

Published in: The American surgeon (2024)

Patients with resectable/borderline resectable PDAC who receive neoadjuvant therapy have longer OS and RFS relative to those who receive upfront surgery.

Keyphrases

locally advanced
neoadjuvant chemotherapy
rectal cancer
squamous cell carcinoma
radiation therapy
sentinel lymph node
liver metastases
minimally invasive
lymph node
free survival
stem cells
early stage
acute coronary syndrome
replacement therapy